Skip to main content
SpringerLink
Log in

Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

There is accumulating clinical evidence that 5-aminosalicylic acid (5-ASA) represents the therapeulc moiety of sulphasalazine in the treatment of inflammatory bowel disease.

For more than 4 decades, the active metabolite, 5-ASA, has been administered in the form of the ‘prodrug’ sulphasalazine; however, in contrast to sulphasalazine, the pharmacokinetics of 5-ASA were unknown until recently. Sulphasalazine itself is poorly absorbed (3 to 12%) and its elimination half-life of about 5 to 10 hours is probably affected by the absorption process. The major part of sulphasalazine is split by bacterial azo-reduction in the colon into 5-ASA and sulphapyridine, the latter accounting for most of the adverse effects of sulphasalazine. The effective cleavage of sulphasalazine depends on an intact colon and transit time. It is markedly reduced in patients taking antibiotics and after removal of the large bowel. The formed sulphapyridine is almost completely absorbed and eliminated by hydroxylation, glucuronidation and polymorphic acetylation. Depending on the genetic phenotype, the elimination half-life and apparent oral clearance of sulphapyridine are approximately 14 hours and 40 ml/min (slow acetylators) or 6 hours and 150 ml/min (fast acetylators), respectively.

Of the 5-ASA released from its ‘vehicle’ sulphapyridine in the colon, at least 25% is absorbed and after acetylation is subsequently excreted in the urine. At least 50% is eliminated in the faeces. Recently, 5-ASA has also been administered directly in the form of enemas, suppositories and oral slow-release preparations. While the elimination half-life of 5-ASA is short (0.5 to 1.5h), its major acetylated metabolite (which may be active) exhibits a half-life of 5 to 10 hours. During therapy with sulphasalazine or 5-ASA, steady-state plasma concentrations of 5-ASA are relatively low (≤ 2 μg/ml); thus its mode of action appears to be topically rather than systemically.

Another approach to deliver the active 5-ASA to the gastrointestinal tract is accomplished with novel ‘prodrugs’ of 5-ASA, in which the carrier molecule sulphapyridine is replaced by 5-ASA itself (azodisalicylate) or other compounds.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Allgayer, H.; Kruis, W. and Paumgartner, G.: Azetylatorstatusunabhängige N-acetyltransferaseaktivität im Kolon bei Patienten mit colitis ulcerosa unter Salfasalazin-Dauertherapie. (Abstract). Zeitschrift für Gastroenterologie 22: 131 (1984).

    Google Scholar 

  • Ashworth, M.; Arthur, M.; Turmer, A.D. and Smith, P.R.: A comparison of serum concentrations of sulphasalazine and some of its metabolites after therapy by the oral or rectal route. Pharmacotherapeutica 3: 551–555 (1984).

    CAS  Google Scholar 

  • Bartalsky, A.: Salicylazobenzoic acid in ulcerative colitis. Lancet 1: 960 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Bates, T.R.; Blumenthal, H.P. and Pieniaszek, H.J.: Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine. Clinical Pharmacology and Therapeutics 22: 917–927 (1977).

    PubMed  CAS  Google Scholar 

  • Berlin. CM. and Yaffe, S.J.: Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Developmental Pharmacology and Therapeutics 1: 31–39 (1980).

    PubMed  CAS  Google Scholar 

  • Binder, V.; Halskov, S.; Hvidberg, E.; Kristensen, E.; Riis, P.; Tougaard, L. and Willumsen, L.: A controlled study of 5-acetylaminosalicylic acid (5-Ac-ASA) as enema in ulcerative colitis. Scandinavian Journal of Gastroenterology 16: 122 (1981).

    Google Scholar 

  • Bondesen, S.; Nielsen, O.H.; Jacobsen, O.; Rasmussen, S.N.; Hansen, S.H.; Halskov, S.; Binder, V. and Hvidberg, E.F.: 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Scandinavian Journal of Gastroenterology 19: 677–682 (1984).

    PubMed  CAS  Google Scholar 

  • Campieri, M.; Lanfanchi, G.A.; Bazzocchi, G.; Brignola, C.; Sarti, F.; Franzin, G.; Battocchia, A.; Labo, G. and Dal Monte, P.R.: Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet 2: 270–271 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Chan, R.P.; Pope, D.J.; Gilbert, A.P.; Sacra, P.J.; Baron, J.H. and Lennard-Jones, J.E.: Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Digestive Diseases and Sciences 28: 609–716 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Clarke, D.F.; George, D.; Milsap, R.L.; Pogonowska-Wala, E.; Owerbach, J.; Lebenthal, E. and Jusko, W.J.: Sulfasalazine metabolite pharmacokinetics in pediatric patients with inflammatory bowel disease: Effects of disease activity, acetylator phenotype and age. Pediatric Pharmacology 2: 323–333 (1982).

    PubMed  CAS  Google Scholar 

  • Cowan, G.O.; Das, K.M. and Eastwood, M.A.: Further studies of sulphasalazine metabolism in the treatment of uicerative colitis. British Medical Journal 2: 1057–1059 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Das, K.M.; Chowdhury, J.R.; Zapp, B. and Fara, J.W.: Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology 77: 280–284 (1979).

    PubMed  CAS  Google Scholar 

  • Das, K.M. and Dubin, R.: Clinical pharmacokinetics of sulphasalazine. Clinical Pharmacokinetics 1: 406–425 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Das, K.M.; Eastwood, M.A.; McManus, J.P.A. and Sircus, W.: The metabolism of salicylazosulphapyridine in ulcerative colitis. Gut 14: 631–641 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Das, K.M.; Eastwood, M.A.; McManus, J.P.A. and Sircus, W.: The role of the colon in the metabolism of salicylazosulphapyridine. Scandinavian Journal of Gastroenterology 9: 137–141 (1974).

    PubMed  CAS  Google Scholar 

  • Dew, M.J.; Cardwell, M.; Kidwai, N.S.; Evans, B.K.; and Rhodes, E.J.: 5-Aminosalicylic acid in serum and urine after administration by enema to patients with colitis. Journal of Pharmacy and Pharmacology 35: 323–324 (1983b).

    Article  PubMed  CAS  Google Scholar 

  • Dew, M.J.; Hughes, P.; Harries, A.D.; Williams, G.; Evans, B.K. and Rhodes, J.: Maintenance of remission in ulcerative colitis with oral preparation of 5-amino salicylic acid. British Medical Journal 285: 1012 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Dew, M.J.; Ryder, R.E.J.; Evans, N.; Evans, B.K. and Rhodes, J.: Colonic release of 5-amino-salicylic acid from an oral preparation in active ulcerative colitis. British Journal of Clinical Pharmacology 16: 185–187 (1983a).

    Article  PubMed  CAS  Google Scholar 

  • Elliott, R.: Crohn’s disease: Drug therapy, diet or surgery. Drugs 21: 383–389 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Fischer, C. and Klotz, U.: High-performance liquid Chromatographic determination of aminosalicylate, sulfapyridine and their metabolites — its application for pharmacokinetic studies with salicylazosulfapyridine in man. Journal of Chromatography 162: 237–243 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Fischer, C. and Klotz, U.: Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn’s disease or ulcerative colitis?. Therapeutic Drug Monitoring 2: 153–158 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Fischer C.; Maier, K.; Stumpf, E.; von Gaisburg, U. and Klotz, U.: Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. European Journal of Clinical Pharmacology 25: 511–515 (1983a).

    Article  PubMed  CAS  Google Scholar 

  • Fischer, C.; Maier, K. and Klotz, U.: Specific measurements of 5-aminosalicylic acid and its acetylated metabolite in human bile. British Journal of Clinical Pharmacology 15: 273–274 (1983b).

    Article  PubMed  CAS  Google Scholar 

  • Fischer, C.; Meese, C.O. and Klotz, U.: A stable isotope method for the quantification of N-acetyl-5-aminosalicylic acid in plasma and urine. Biomedical Mass Spectrometry 11: 539–544 (1984).

    Article  PubMed  CAS  Google Scholar 

  • Garretto, M.; Riddell, R.H. and Winans, C.S.: Treatment of chronic ulcerative colitis with poly-ASA: A new nonabsorbable carrier for release of 5-aminosalicylate in the colon. Gastroenterology 84: 1162 (1983).

    Google Scholar 

  • Goldstein, P.D.; Alpers, D.H. and Keating, J.P.: Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine. Journal of Pediatrics 95: 638–640 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Hanngren, A.; Hansson, E.; Svartz, N. and Ullberg, S.: Distribution and metabolism of salicyl-azo-sulfapyridine. I. A study with C14-salicyl-azo-sulfapyridine and C15-5-aminosalicylic acid. Acta Medica Scandinavica 173: 61–72 (1963a).

    Article  PubMed  CAS  Google Scholar 

  • Hanngren, Å.; Hansson, E.; Svartz, N. and Ullberg, S.: Distribution and metabolism of salicyl-azo-sulfapyridine. II. A study with S35-salicyl-azo-sulfapyridine and S35-sulfapyridine. Acta Medica Scandinavica 173: 391–399 (1963b).

    Article  PubMed  CAS  Google Scholar 

  • van Hees, P.A.M.; Bakker, H.J. and van Tongeren, J.H.M.: Effect of sulfapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: A study to determine the active therapeutic moiety of sulphasalazine. Gut 21: 623–635 (1980).

    Google Scholar 

  • van Hees, P.A.M.; Tuinte, J.H.M.; van Rossum, J.M. and van Tongeren, J.H.M.: Influence of intestinal transit time on azoreduction of salicylazosulphapyridine (Salazopyrin). Gut 20: 300–304 (1979).

    Article  PubMed  Google Scholar 

  • Hensleigh, P.A. and Kauffman, R.E.: Maternal absorption and placental transfer of sulfasalazine. American Journal of Obstetrics and Gynecology 127: 443–444 (1977).

    PubMed  CAS  Google Scholar 

  • Houston, J.B.; Day, J. and Walker, J.: Azo reduction of sulphasalazine in healthy volunteers. British Journal Clinical Pharmacology 14: 395–398 (1982).

    Article  CAS  Google Scholar 

  • Jansen, J.A.: Kinetics of the binding of salicylazosulfapyridine to human serum albumin. Acta Pharmacologica et Toxicologica 41: 401–416 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Järnerot, G. and Into-Malmberg, M.-B.: Sulphasalazine treatment during breast feeding. Scandinavian Journal of Gastroenterology 14: 869–871 (1979).

    Article  PubMed  Google Scholar 

  • Järnerot, G.; Into-Malmberg, M.-B. and Esbjörner, E.: Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scandinavian Journal of Gastroenterology 16: 693–697 (1981).

    Article  PubMed  Google Scholar 

  • Khan, A.K.A.; Guthrie, G.; Johnston, H.H.; Truelove, S.C. and Williamson, D.H.: Tissue and bacterial splitting of sulphasalazine. Clinical Science 64: 349–354 (1983a).

    CAS  Google Scholar 

  • Khan, A.K.A.; Nurrazzaman, M. and Truelove, S.C: The effect of the acetylator phenotype on the metabolism of sulphasalazine in man. Journal of Medical Genetics 20: 30–36 (1983b).

    Article  Google Scholar 

  • Khan, A.K.A.; Piris, J. and Truelove, S.C.: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2: 892–895 (1977).

    Article  Google Scholar 

  • Khan, A.K.A. and Truelove, S.C.: Placental and mammary transfer of sulphasalazine. British Medical Journal 2: 1553 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Khan, A.K.A. and Truelove, S.C.: Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis. Gut 21: 706–710 (1980).

    Article  Google Scholar 

  • Khan, A.K.A.; Truelove, S.C. and Aronson, J.K.: The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. British Journal of Clinical Pharmacology 13: 523–528 (1982).

    Google Scholar 

  • Klotz, U.: Pathophysiological and disease-induced changes in distribution volume: Pharmacokinetic implications. Clinical Pharmacokinetics 1: 204–218 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Klotz, U.; Maier, K.E.; Fischer, C. and Bauer, K.H.: A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease: Biopharmaceutic and clinical pharmacokinetic characteristics. Arzneimittel-Forschung 35: 636–639 (1985).

    PubMed  CAS  Google Scholar 

  • Klotz, U.; Maier, K.; Fischer, C. and Heinkel, K.: Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. New England Journal of Medicine 303: 1499–1502 (1980).

    Article  PubMed  CAS  Google Scholar 

  • Kruis, W.; Büll, U.; Eisenburg, J. and Paumgartner, G.: Retrograde colonic spread of sulphasalazine enemas. Scandinavian Journal of Gastroenterology 17: 933–938 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Lauritsen, K.; Hansen, J.; Ryde, M. and Rask-Madsen, J.: Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis. Gastroenterology 86: 1496–1500 (1984).

    PubMed  CAS  Google Scholar 

  • Meese, C.O.; Fischer, C. and Klotz, U.: Is N-acetylation of 5-aminosalicyclic acid reversible in man?. British Journal of Clinical Pharmacology 18: 612–615 (1984).

    Article  PubMed  CAS  Google Scholar 

  • Nielsen, O.H. and Bondesen, S.: Kinetics of 5-aminosalicyclic acid after jejunal instillation in man. British Journal of Clinical Pharmacology 16: 738–740 (1983).

    Article  CAS  Google Scholar 

  • Northfield, T.C.: Ulcerative colitis and Crohn’s colitis: Differential diagnosis and treatment. Drugs 14: 198–206 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Nygård, B.; Olofsson, J. and Sandberg, M.: Some physico-chemical properties of salicylazosulphapyridine, including its solubility, protolytic constants and general spectrochemical and polarographic behaviour. Acta Pharmaceutica Suecica 3: 313–342 (1966).

    PubMed  Google Scholar 

  • Peppercorn, M.A.: Sulfasalazine — pharmacology, clinical use, toxicity, and related new drug development. Annals of Internal Medicine 3: 377–386 (1984).

    Google Scholar 

  • Peppercorn, M.A. and Goldman, P.: The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. Journal of Pharmacology and Experimental Therapeutics 181: 555–562 (1972).

    PubMed  CAS  Google Scholar 

  • Peppercorn. M.A. and Goldman, P.: Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 64: 240–245 (1973).

    PubMed  CAS  Google Scholar 

  • Pieniaszek, H.J. and Bates, T.R.: Capacity-limited gut wall metabolism of 5-amino-salicylic acid, a therapeutically active metabolite of sulfasalazine, in rats. Journal of Pharmaceutical Sciences 68: 1323–1325 (1979).

    Article  PubMed  CAS  Google Scholar 

  • Pieniaszek, H.J.; Resetaritis, D.E.; Wilferth, W.W.; Blumenthal, H.P. and Bates, T.R.: Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets. Journal of Clinical Pharmacology 19: 39–45 (1979).

    PubMed  CAS  Google Scholar 

  • Rasmussen, S.N.; Binder, V.; Maier, K.; Bondesen, S.; Fischer, C.; Klotz, U.; Hansen, S.H. and Hvidberg, E.F.: Treatment of Crohn’s disease with peroral 5-aminosalicylic acid. Gastroenterology 85: 1350–1353 (1983).

    PubMed  CAS  Google Scholar 

  • Ryde, E.M. and Lima, J.J.: Bioavailability study on oral sulfasalazine suspension compared to tablets in healthy volunteers. Current Therapeutic Research 29: 728–737 (1981).

    Google Scholar 

  • Sandberg-Gertzén, H.; Ryde, M. and Järnerot, G.: Absorption and excretion of azodisal sodium and metabolites in man after rectal administration of a single 2-g dose. Scandinavian Journal of Gastroenterology 18: 571–575 (1983a).

    Article  PubMed  Google Scholar 

  • Sandberg-Gertzén, H.; Ryde, M. and Järnerot, G.: Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy. Scandinavian Journal of Gastroenterology 18: 107–111 (1983b).

    Article  PubMed  Google Scholar 

  • Schröder, H. and Campbell, D.E.S.: Absorption, metabolism and excretion of salicylazosulfapyridine in man. Clinical Pharmacology and Therapeutics 13: 539–551 (1972).

    PubMed  Google Scholar 

  • Schröder, H. and Evans, D.A.P.: Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut 13: 278–284 (1972).

    Article  PubMed  Google Scholar 

  • Schröder, H. and Gustafsson, B.E.: Azo reduction of salicyl-azo-sulphapyridine in germ-free and conventional rats. Xenobiotica 3: 225–231 (1973).

    Article  PubMed  Google Scholar 

  • Schröder, H.; Lewkonia, R.M. and Evans, D.A.P.: Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Clinical Pharmacology and Therapeutics 14: 802–809 (1973).

    PubMed  Google Scholar 

  • Singleton, J.W.; Law, D.H.; Kelley Jr, M.L.; Makhjian, H.S. and Sturdevant, R.A.L.: National cooperative Crohn’s disease study: Adverse reactions to study drugs. Gastroenterology 77: 870–882 (1979).

    PubMed  CAS  Google Scholar 

  • Svartz, N.: Salazopyrin, a new sulfanilamide preparation. Acta Medica Scandinavica 110: 577–598 (1942).

    Article  Google Scholar 

  • Taffet, S.L. and Das, K.M.: Sulfasalazine — adverse effects and desensitization. Digestive Diseases and Sciences 28: 833–842 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Toovey, S.; Hudson, E.; Hendry, W.F. and Levi, A.J.: Sulphasalazine and male infertility: Reversibility and possible mechanism. Gut 22: 445–451 (1981).

    Article  PubMed  CAS  Google Scholar 

  • Vree, T.B.; Tijhius, M.W.; Baakman, M. and Hekster, C.A.: Analysis of N4-trideuteroacetylsulphamerazine and its metabolites sulphamerazine and N4-acetylsulphamerazine in man by means of high-performance liquid chromatography and mass spectrometry. Biomedical Mass Spectrometry 10: 114–119 (1983).

    Article  PubMed  CAS  Google Scholar 

  • Willoughby, C.P.; Aronson, J.K.; Agback, H.; Bodin, N.O. and Truelove, S.C.: Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut 23: 1081–1087 (1982).

    Article  PubMed  CAS  Google Scholar 

  • Willoughby, C.P.; Piris, J. and Truelove, C.: The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis. Scandinavian Journal of Gastroenterology 15: 715–719 (1980).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dr Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Auerbachstr. 112, D-7000, Stuttgart 50, West Germany

    Ulrich Klotz

Authors
  1. Ulrich Klotz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Klotz, U. Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicylic Acid. Clin Pharmacokinet 10, 285–302 (1985). https://doi.org/10.2165/00003088-198510040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198510040-00001

Keywords

Search

Navigation